Shaping next decade of systemic therapy for head and neck squamous cell carcinoma: where do we go next?

Outcomes of patients with relapsed or metastatic head and neck squamous cell carcinoma (R/M HNSCC) remain poor, despite the widespread incorporation of immune checkpoint inhibitors into contemporary treatment algorithms. Although programmed death-1 (PD-1) blockade with pembrolizumab, administered ei...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Michael Saerens, Tijl Vermassen, Jenas Stevenheydens, Willem Lybaert
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Frontiers Media S.A. 2026-03-01
Ráidu:	Frontiers in Oncology
Fáttát:	bispecific antibodies head and neck squamous cell carcinoma HNSCC immune checkpoint inhibitor immunotherapy oncolytic vaccines
Liŋkkat:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1799378/full
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!